Myriad Genes (MYGN) Higher Second Quarter Earnings, Gross Margin Low

Myriad Genetics, Inc. MYGN reported adjusted earnings per share (EPS) of 4 cents within the second quarter of 2022, topping Zacks’ consensus estimate for adjusted earnings per share of two cents. Nonetheless, the measure is down 66.7% from final 12 months’s quarter determine of 12 cents. Quarter changes exclude some takeovers — amortization of intangible … Read more